PRFZ - PowerShares FTSE RAFI US 1500 Sm-Mid ETF

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
-1.26 (-0.95%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close132.98
Bid0.00 x 0
Ask0.00 x 0
Day's Range130.40 - 132.23
52 Week Range112.11 - 136.76
Avg. Volume55,156
Net Assets1.87B
PE Ratio (TTM)N/A
YTD Return-1.89%
Beta (3y)0.96
Expense Ratio (net)0.39%
Inception Date2006-09-20
Trade prices are not sourced from all markets
  • What Are Insys Therapeutics’ Top Priorities?
    Market Realist2 months ago

    What Are Insys Therapeutics’ Top Priorities?

    Insys (INSY) is taking strategic steps to restore stakeholder confidence. The company aims to achieve one NDA (or new drug application) per year over the next five years. Insys is targeting treatments for orphan diseases, neurological diseases like pediatric epilepsy, genetic conditions like Prader-Willi syndrome, and treatments for secondary allergic reactions, anorexia, and products for opioid overdose.

  • Morningstar11 months ago

    Contrarian Rebalancing Gives This Earnings-Focused ETF an Edge

    WisdomTree MidCap Earnings' rebalancing approach should keep its valuation in check.

  • We're sorry this is all we were able to find about this topic.